(Q35552638)

8 August 2017

1 reference

title

Andropause: symptom management for prostate cancer patients treated with hormonal ablation (English)

1 reference

8 August 2017

Andropause: Symptom Management for Prostate Cancer Patients Treated With Hormonal Ablation (English)

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

18 March 2024

1 reference

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

18 March 2024

2

Tait D Shanafelt

1 reference

8 August 2017

Carrie A. Thompson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14530501

18 March 2024

Charles L. Loprinzi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14530501

18 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14530501

18 March 2024

publication date

1 January 2003

1 reference

full work available at URL

8 August 2017

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.8-5-474

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

https://onlinelibrary.wiley.com/doi/full-xml/10.1634/theoncologist.8-5-474

18 March 2024

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

https://academic.oup.com/oncolo/article-pdf/8/5/474/41840311/oncolo_8_5_474.pdf

18 March 2024

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

18 March 2024

1 reference

8 August 2017

volume

8

1 reference

8 August 2017

issue

5

1 reference

8 August 2017

page(s)

474-487

1 reference

Andropause: clinical implications of the decline in serum testosterone levels with aging in men.

8 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Potentially predictive and manipulable blood serum correlates of aging in the healthy human male: progressive decreases in bioavailable testosterone, dehydroepiandrosterone sulfate, and the ratio of insulin-like growth factor 1 to growth hormone

18 March 2024

3

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Clinical review 24: Androgens in the aging male

18 March 2024

4

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Sex hormones and age: a cross-sectional study of testosterone and estradiol and their bioavailable fractions in community-dwelling men.

18 March 2024

5

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Long-term longitudinal measurements of plasma dehydroepiandrosterone sulfate in normal men

18 March 2024

6

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Growth hormone, body composition, and aging

18 March 2024

7

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Validation of a screening questionnaire for androgen deficiency in aging males

18 March 2024

8

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

18 March 2024

Androgens and aging

9

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Effects of human growth hormone in men over 60 years old

18 March 2024

10

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial

18 March 2024

11

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

18 March 2024

12

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

18 March 2024

Cancer statistics, 2002

13

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Controversies surrounding androgen deprivation for prostate cancer

18 March 2024

15

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

STUDIES ON PROSTATIC CANCER

18 March 2024

17

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

18 March 2024

19

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Flushing. Long-term side effect of orchiectomy in treatment of prostatic carcinoma

18 March 2024

20

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer

18 March 2024

21

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma.

18 March 2024

22

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Pathophysiology and treatment of hot flashes

18 March 2024

23

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Methodologic lessons learned from hot flash studies

18 March 2024

24

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Treatment of post-orchiectomy hot flashes with transdermal administration of clonidine

18 March 2024

25

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Cyproterone acetate in treatment of post-orchidectomy hot flushes. Double-blind cross-over trial

18 March 2024

27

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

A prospective comparison of treatments for symptomatic hot flushes following endocrine therapy for carcinoma of the prostate

18 March 2024

28

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Treatment of castration-induced menopausal symptoms with low dose diethylstilbestrol in men with advanced prostate cancer

18 March 2024

29

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Diethylstilbestrol in treatment of postorchiectomy vasomotor symptoms and its relationship with serum follicle-stimulating hormone, luteinizing hormone, and testosterone

18 March 2024

30

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Transdermal estrogen in the treatment of hot flushes in men with prostate cancer

18 March 2024

31

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Orchidectomy versus oestrogen for prostatic cancer: cardiovascular effects

18 March 2024

32

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Megestrol Acetate for the Prevention of Hot Flashes

18 March 2024

33

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes

18 March 2024

34

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome

18 March 2024

35

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Prostate-specific antigen response to withdrawal of megestrol acetate in a patient with hormone-refractory prostate cancer

18 March 2024

36

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer

18 March 2024

38

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial

18 March 2024

39

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors.

18 March 2024

41

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Sertraline relieves hot flashes secondary to medical castration as treatment of advanced prostate cancer

18 March 2024

42

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Gabapentin's effects on hot flashes and hypothermia

18 March 2024

43

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Gabapentin for hot flashes in prostate cancer

18 March 2024

44

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Pilot evaluation of gabapentin for treating hot flashes

18 March 2024

45

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study

18 March 2024

47

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Mortality after all major types of osteoporotic fracture in men and women: an observational study.

18 March 2024

49

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation

18 March 2024

51

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

18 March 2024

Sex steroids and bone

52

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man

18 March 2024

54

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens

18 March 2024

55

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency

18 March 2024

56

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Effect of testosterone and estradiol in a man with aromatase deficiency

18 March 2024

57

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo Study

18 March 2024

58

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men

18 March 2024

59

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma

18 March 2024

61

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer

18 March 2024

62

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer

18 March 2024

63

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.

18 March 2024

64

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Progressive osteoporosis during androgen deprivation therapy for prostate cancer

18 March 2024

65

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Androgen deprivation therapy for prostate cancer results in significant loss of bone density

18 March 2024

66

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs

18 March 2024

67

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists

18 March 2024

69

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy

18 March 2024

70

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Low bone mineral density in hormone-naïve men with prostate carcinoma

18 March 2024

71

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Alendronate for the Treatment of Osteoporosis in Men

18 March 2024

74

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer

18 March 2024

76

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study

18 March 2024

77

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens

18 March 2024

78

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

The effect of micronized estradiol on bone turnover and calciotropic hormones in older men receiving hormonal suppression therapy for prostate cancer

18 March 2024

79

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Osteoporosis during androgen deprivation therapy for prostate cancer

18 March 2024

80

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Osteoporosis due to androgen deprivation therapy in men with prostate cancer

18 March 2024

81

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Androgens and erythropoiesis

18 March 2024

83

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Androgens and Erythropoiesis

18 March 2024

85

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

18 March 2024

Anemia After Orchiectomy

86

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Effect of reversible androgen deprivation on hemoglobin and serum immunoreactive erythropoietin in men

18 March 2024

87

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade.

18 March 2024

88

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Development of anemia and recovery in prostate cancer patients treated with combined androgen blockade and radiotherapy

18 March 2024

89

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology

18 March 2024

90

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Anemia associated with advanced prostatic adenocarcinoma: effects of recombinant human erythropoietin

18 March 2024

91

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Efficacy of epoetin beta on hemoglobin, quality of life, and transfusion needs in patients with anemia due to hormone-refractory prostate cancer--a randomized study.

18 March 2024

92

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Predictors of skeletal muscle mass in elderly men and women.

18 March 2024

94

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

18 March 2024

Sarcopenia

95

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age

18 March 2024

97

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

An integrative review on current evidence of testosterone replacement therapy for the andropause

18 March 2024

98

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Fatigue in patients with prostate cancer receiving hormone therapy.

18 March 2024

99

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Gynecomastia in patients with prostate cancer: a review of treatment options

18 March 2024

101

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Side effects of endocrine treatment and their mechanisms: castration, antiandrogens, and estrogens.

18 March 2024

102

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Prevention of Gynecomastia by Local Roentgen Irradiation in Estrogen-Treated Prostatic Carcinoma

18 March 2024

103

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Pre-Estrogen Breast Irradiation for Patients with Carcinoma of the Prostate: A Critical Review

18 March 2024

104

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Bilateral mastectomy and irradiation in the prevention of estrogen induced gynecomastia

18 March 2024

105

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Subareolar mastectomy to prevent estrogen-induced male breast enlargement: a new procedure for use in patients with carcinoma of the prostate

18 March 2024

106

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Psychological and behavioural effects of endogenous testosterone levels and anabolic-androgenic steroids among males. A review

18 March 2024

107

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Total and free testosterone in depressed men

18 March 2024

108

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Salivary testosterone levels and major depressive illness in men.

18 March 2024

109

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial.

18 March 2024

110

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Plasma testosterone levels, depression, sexuality, and age

18 March 2024

111

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo Study

18 March 2024

112

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Testosterone replacement therapy for hypogonadal men with SSRI-refractory depression

18 March 2024

115

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Depression during hormonal treatment of prostate cancer

18 March 2024

116

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Effect of testosterone deprivation on the cognitive performance of a patient with Alzheimer's disease.

18 March 2024

117

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial.

18 March 2024

118

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Defining an international research agenda for quality of life in men with prostate cancer

18 March 2024

119

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Quality-of-life outcomes in long-term survivors of advanced prostate cancer

18 March 2024

120

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

The quality of life of patients with newly diagnosed M1 prostate cancer: experience with EORTC clinical trial 30853.

18 March 2024

121

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study

18 March 2024

122

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Quality of life in advanced prostate cancer: results of a randomized therapeutic trial.

18 March 2024

123

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

18 March 2024

124

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

A comparison of the quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy

18 March 2024

125

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Coping and health-related quality of life in men with prostate cancer randomly assigned to hormonal medication or close monitoring

18 March 2024

127

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report

18 March 2024

128

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study

18 March 2024

129

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Sexual dysfunction in the United States: prevalence and predictors

18 March 2024

130

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Testosterone replacement therapy and sleep-related erections in hypogonadal men

18 March 2024

131

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Changes in erectile responsiveness during androgen replacement therapy

18 March 2024

132

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

The nature of androgen action on male sexuality: a combined laboratory-self-report study on hypogonadal men.

18 March 2024

133

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Pilot study of the transdermal application of testosterone gel to the penile skin for the treatment of hypogonadotropic men with erectile dysfunction

18 March 2024

136

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Testosterone for erectile failure

18 March 2024

137

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Sexual function in prostatic cancer patients treated with radiotherapy, orchiectomy or oestrogens.

18 March 2024

138

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Intermittent endocrine therapy for advanced prostate cancer

18 March 2024

139

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Long-term effects of androgen deprivation therapy in prostate cancer patients

18 March 2024

140

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Erectile function and nocturnal penile tumescence in patients with prostate cancer undergoing luteinizing hormone-releasing hormone agonist therapy

18 March 2024

141

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group

18 March 2024

142

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group

18 March 2024

143

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group

18 March 2024

144

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-474

18 March 2024

Identifiers

1 reference

8 August 2017

1 reference